Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor
Дата публикации: 12-10-2026 07:00:00

Findings from the evERA study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Empresas.- Giredestrant con everolimus mejora la supervivencia libre de progresión en un tipo de cáncer de mama avanzado04.5716-10-2026
2FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally Advanced or metastatic breast cancer014.9109-09-2026
3Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
4Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer018.8530-07-2026
5Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma5730-06-2026
6Nivolumab-Ipilimumab for Gastric/Gastroesophageal Junction Adenocarcinoma017.2515-10-2026
7FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma03014-10-2026
8PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review08.3416-07-2026
9Un estudio halla una combinación de fármacos eficaz contra el cáncer de endometrio05.2918-09-2026
10Pembrolizumab Plus Chemotherapy for Cervical Cancer014.7610-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 25.38. Источник: www.esmo.org.